Drugs / ASP3026
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01401504 | May 2011 → Jan 2014 | cancer | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT01284192 | Dec 2010 → Feb 2014 | B-cell neoplasm, cancer | Astellas Pharma Inc | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP3026 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01284192 ↗ |
| Action | Inhibit | “anaplastic lymphoma kinase (ALK) inhibitor” PMID 26966027 ↗ Mar 2016 |
| Modality | Small molecule | — CHEMBL3545360 ↗ |
| Route | Oral | “Advanced solid tumor patients received oral ASP3026” PMID 26966027 ↗ Mar 2016 |
| Target | ALK | “anaplastic lymphoma kinase (ALK) inhibitor” PMID 26966027 ↗ Mar 2016 |